News und Analysen
![AbbVie Analysts Lead the Stock Higher as Humira Worries Recede: https://www.marketbeat.com/logos/articles/med_20240730104221_chart-abbv-7303034.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNHZtYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--35b89d873153e1f089b95f53e8fe2a230988c29a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240730104221_chart-abbv-7303034.png?locale=de)
AbbVie Analysts Lead the Stock Higher as Humira Worries Recede
AbbVie (NYSE: ABBV) was among the pharma companies worst positioned for a patent cliff that has come and gone. However, management's lean toward diversifying away from Humira and into a broader
![Pharma Stock Cuts Earnings Outlook: Still a Buying Opportunity: https://www.marketbeat.com/logos/articles/med_20240730092816_mrkchart730.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMkRtYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--dd4bd97e9b2e9c99997c053ac511b23dca201c57/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240730092816_mrkchart730.png?locale=de)
Pharma Stock Cuts Earnings Outlook: Still a Buying Opportunity
Merck & Co. Inc. (NYSE: MRK) delivered a solid earnings report before the market opened on July 30, 2024. However, the stock was down over 4% in early trading after the company cut its full-year
![Top 2 Cheap Healthcare Stocks to Buy as Sector Outperforms: https://www.marketbeat.com/logos/articles/med_20240729132408_healthcare-sector-outperforms-2-cheap-healthcare-s.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBKy9sYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--3d9a042db8c33319140332cda195852f33ba54b8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240729132408_healthcare-sector-outperforms-2-cheap-healthcare-s.jpg?locale=de)
Top 2 Cheap Healthcare Stocks to Buy as Sector Outperforms
As the second half of the year has gotten underway, the healthcare sector, represented by the XLV ETF, has seen a notable resurgence. This sector, which had been underperforming since the
![Is This Telehealth Stock a Buy After the Recent Pullback?: https://www.marketbeat.com/logos/articles/med_20240719104001_is-this-telehealth-stock-a-buy-after-the-recent-pu.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN3ZhYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--541dc31566e309ab26e834e21163c2ccb79ad4d4/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240719104001_is-this-telehealth-stock-a-buy-after-the-recent-pu.jpg?locale=de)
Is This Telehealth Stock a Buy After the Recent Pullback?
Hims & Hers Health, Inc. (NYSE: HIMS) is a prominent player in the telehealth sector, which is part of the larger healthcare sector. The company has garnered significant attention from
![Pharma Leader Beats on Earnings, But Shares Fall: https://www.marketbeat.com/logos/articles/med_20240719074321_pharma-leader-beats-on-earnings-but-shares-fall.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNlRhYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--d62b35e153ab923e10ed2932538724ec55747ce7/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240719074321_pharma-leader-beats-on-earnings-but-shares-fall.jpg?locale=de)
Pharma Leader Beats on Earnings, But Shares Fall
Novartis (NYSE:NVS) is the seventh largest pharmaceutical company in the world, and is based in Switzerland. The firm reported Q2 2024 financial results on Jul. 18, 2024. The company is performing
![Why This Leading Health Stock is a Buy No Matter the Market Move: https://www.marketbeat.com/logos/articles/med_20240718074551_chart-abt-7182024.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMURaYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--d3293d75b81fe2b099789a407dbbafa997e12be5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240718074551_chart-abt-7182024.png?locale=de)
Why This Leading Health Stock is a Buy No Matter the Market Move
Abbott Laboratories (NYSE: ABT) is a premier buy-and-hold stock because of its foresightful management, quality operation, portfolio, pipeline, cash flow, and capital return. It’s not always a
![Why This Healthcare Stock is a Strong Buy Despite Headwinds: https://www.marketbeat.com/logos/articles/med_20240716075118_chart-unh-7162024ver001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM25YYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--dec71f4e8f1aa03c6e044467887bd7e1caae5f40/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240716075118_chart-unh-7162024ver001.png?locale=de)
Why This Healthcare Stock is a Strong Buy Despite Headwinds
UnitedHealth Group (NYSE: UNH) has headwinds, but its healthcare business and operational quality offset them, setting the stock to hit new all-time highs. The primary culprit is the recent
![Strategic Buy Lights Up This Biotech Stock: Time to Invest?: https://www.marketbeat.com/logos/articles/med_20240715092117_chartm-ilmn.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK0xWYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--043b37e0d4b42e7edffe9bf194d0d64e594b7298/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240715092117_chartm-ilmn.jpg?locale=de)
Strategic Buy Lights Up This Biotech Stock: Time to Invest?
Life sciences company Illumina Inc. (NASDAQ: ILMN) stock surged over 10% following its announcement of the acquisition of Fluent Biosciences. This comes after its divestiture and spin-off of
![CPI Data Sparks Rally in Biotech Stocks: https://www.marketbeat.com/logos/articles/med_20240715071929_cpi-data-sparks-rally-in-biotech-stocks.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeEhWYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--e72f3b13512241325fe9269e941b19b6d92017b2/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240715071929_cpi-data-sparks-rally-in-biotech-stocks.jpg?locale=de)
CPI Data Sparks Rally in Biotech Stocks
The biotech sector has significantly lagged behind the overall market and its leading sector, technology, year-to-date. However, following the release of the CPI data on Thursday, the biotech
![Positive News is Driving This Cancer Drug Maker’s Stock Higher: https://www.marketbeat.com/logos/articles/med_20240712145036_positive-news-is-driving-this-cancer-drug-makers-s.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOFBVYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--0b4695fe05fb28e3a5bf4c6d6850c0f5cf5b86c1/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240712145036_positive-news-is-driving-this-cancer-drug-makers-s.jpg?locale=de)
Positive News is Driving This Cancer Drug Maker’s Stock Higher
Shares of IDEAYA Biosciences Inc. (NASDAQ: IDYA) are up more than 16% after announcing positive treatment data for its Phase 2 clinical trial. The company’s pipeline candidate, IDE397, is an
![Top 4 Must-Have Healthcare Stocks for Long-Term Growth: https://www.marketbeat.com/logos/articles/med_20240711100558_top-4-must-have-healthcare-stocks-for-long-term-gr.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBenpTYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--18c796118b42c488d1d1d9cbb3a7bd30f51bb02d/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240711100558_top-4-must-have-healthcare-stocks-for-long-term-gr.jpg?locale=de)
Top 4 Must-Have Healthcare Stocks for Long-Term Growth
The healthcare industry represents a substantial and dynamic market sector, presenting many opportunities for investors seeking long-term growth and stability. Factors such as the aging
![3 Stock Giants Analysts Are Bullish On Despite Struggles: https://www.marketbeat.com/logos/articles/med_20240705084239_3-stock-giants-analysts-are-bullish-on-despite-str.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM2pNYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--36338d066fa488a0781448b3590f0ae903c560ae/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240705084239_3-stock-giants-analysts-are-bullish-on-despite-str.jpg?locale=de)
3 Stock Giants Analysts Are Bullish On Despite Struggles
Despite their recent struggles, these three industry giants hold the promise of significant upside. With favorable consensus price targets and ratings, attractive P/E valuations, solid earnings
![AbbVie Stock: A Perfect Dip for Investors to Buy: https://www.marketbeat.com/logos/articles/med_20240703114110_abbvie-stock-a-perfect-dip-for-investors-to-buy.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNlBLYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--e1651021aac3b24b026a6e208b07dee84c6d0453/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240703114110_abbvie-stock-a-perfect-dip-for-investors-to-buy.jpg?locale=de)
AbbVie Stock: A Perfect Dip for Investors to Buy
In a holiday-shortened week, shares of AbbVie Inc. (NYSE: ABBV) are down a little more than 3%. To put that in context, the drop in ABBV stock was more than that of biotech stocks such as Johnson
![Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex: https://www.marketbeat.com/logos/articles/med_20240702093329_biotech-stock-breakout-ibb-eyes-major-resistance-l.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNHpKYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--e1f840deea42e5150ac458dea84be6d0b2aaa4dd/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240702093329_biotech-stock-breakout-ibb-eyes-major-resistance-l.jpg?locale=de)
Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
The biotechnology sector, represented by the iShares Biotechnology ETF (NASDAQ: IBB), has experienced a year of consolidation. With the ETF up just 0.8%, it has underperformed the broader market
![Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes: https://www.marketbeat.com/logos/articles/med_20240701132023_charty-pfe.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBelBKYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a916f7815ba19e6afa8bd22bd075b1df40f60536/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240701132023_charty-pfe.jpg?locale=de)
Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes
Pharmaceutical giant Pfizer Inc. (NYSE: PFE) has been trying to enter the weight-loss treatment trend dominated by GLP-1 drug makers like Ozempic and Wegovy makers Novo Nordisk A/S (NYSE: NVO) a
![Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market: https://www.marketbeat.com/logos/articles/med_20240630174256_charty-lly.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMXJJYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--1ac61e5394abb0f95cf1314afe9071803f9c5d14/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240630174256_charty-lly.jpg?locale=de)
Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Global pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) has made headlines with its leading GLP-1 weight loss drugs, Mounjaro and Zepbound. Mounjaro is prescribed for Type 2 diabetes but is
![Sarepta Therapeutics Stock Soars on FDA Approval: https://www.marketbeat.com/logos/articles/med_20240621103734_sarepta-therapeutics-stock-soars-on-fda-approval.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBODYvYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--7a9802db2326ffdca0a83b4bd26865118d319d48/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240621103734_sarepta-therapeutics-stock-soars-on-fda-approval.jpg?locale=de)
Sarepta Therapeutics Stock Soars on FDA Approval
Sarepta Therapeutics (NASDAQ: SRPT) is leading the game in precision genetic medicine and biotechnology. Sarepta Therapeutics' stock price has witnessed a surge of over 40% after receiving
![Centene Reaffirms Guidance, But Is it Too Late?: https://www.marketbeat.com/logos/articles/med_20240602155058_chart-cnc.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBenV1YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--0192a143d80992412d1de3299291a60fe5b90666/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240602155058_chart-cnc.jpg?locale=de)
Centene Reaffirms Guidance, But Is it Too Late?
Managed care health insurance company Centene Inc. (NYSE: CNC) recently saw its share rebound after reaffirming its guidance. This move came just after UnitedHealth Group Inc. (NYSE: UNH) made
![Hims & Hers Health Soars on Generic GLP-1 Rollout Plans: https://www.marketbeat.com/logos/articles/med_20240602154511_charte-hims.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNStzYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--2a2ca0bdb183d7855e2f8c0e0d299519cdbc8069/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240602154511_charte-hims.jpg?locale=de)
Hims & Hers Health Soars on Generic GLP-1 Rollout Plans
Him & Hers Health Inc. (NYSE: HIMS) provides a direct-to-consumer (DTC) health and wellness platform. The company was best known for prescribing treatments for erectile dysfunction (ED) through
![Determining Your Risk Tolerance - A Comprehensive Guide: https://www.marketbeat.com/logos/articles/med_20240529082231_determining-your-risk-tolerance---a-comprehensive.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeEdvYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9a2e912cd33484117c98fb851e06642931a71a1e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240529082231_determining-your-risk-tolerance---a-comprehensive.jpg?locale=de)
Determining Your Risk Tolerance - A Comprehensive Guide
Risk tolerance varies from person to person. Some people have no fear of parachuting out of an airline, while others won’t even ride a rollercoaster at a theme park. Everyone is a combination of
![Is Cigna Group the Nation's Best-Run Health Insurance Company?: https://www.marketbeat.com/logos/articles/med_20240525153829_chart-ci.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNFdtYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--68d13e950e219caf7e551b20d51067899d3c79ca/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240525153829_chart-ci.jpg?locale=de)
Is Cigna Group the Nation's Best-Run Health Insurance Company?
Health insurance companies in the medical sector have not fared well in 2024. Medicare Advantage (MA) plans were a bountiful source of income until the second half of 2023. Humana Inc. (NYSE: HUM)
![Medtronic Dips: Is Now the Time to Buy?: https://www.marketbeat.com/logos/articles/med_20240523121523_chart-mdt-5232024ver001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMStrYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--51dd10f824583be3c4c9164bb9bdfe98bed38779/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240523121523_chart-mdt-5232024ver001.png?locale=de)
Medtronic Dips: Is Now the Time to Buy?
Shares of Medtronic (NYSE: MDT) are falling following its FQ4 release and guidance, opening up a potential buying opportunity. The question is whether its value, yield, balance sheet and cash flow
![CVS Health Stock Has a Silver Lining Called Value: https://www.marketbeat.com/logos/articles/med_20240519153028_chartzy-cvs.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNVNlYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--7eec854770c4c9d9d0c4acb291fbda148767fdde/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240519153028_chartzy-cvs.jpg?locale=de)
CVS Health Stock Has a Silver Lining Called Value
Integrated healthcare retailer and insurer CVS Health Co. (NYSE: CVS) stock presents a value not seen in years. The medical sector giant saw its shares punished on its Q1 2024 top and bottom line
![Will the Biotech Sector Shift From Lagger to Leader?: https://www.marketbeat.com/logos/articles/med_20240509132613_will-the-biotech-sector-shift-from-lagger-to-leade.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK1NVYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--050598f27ddedea95cd79ba7fec938f18598f13c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240509132613_will-the-biotech-sector-shift-from-lagger-to-leade.jpg?locale=de)
Will the Biotech Sector Shift From Lagger to Leader?
The biotech sector and its popular ETF, the iShares Biotechnology ETF (NASDAQ: IBB), have lagged the overall market during the year, with its shares slightly red. However, in recent weeks, the
![AbbVie Tracking for New Highs in 2024: https://www.marketbeat.com/logos/articles/med_20240507101742_chart-abbv-572024.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBd0tRYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--b56d89d208605198aa5db2b2dac94a7ab5ed6263/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240507101742_chart-abbv-572024.png?locale=de)
AbbVie Tracking for New Highs in 2024
Shares of AbbVie (NYSE: ABBV) fell hard in the wake of its Q1 earnings report, but the dip is over. The market response to slowing Humira sales is overshadowed by strength in the non-Humira